Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$247M |
| 2 |
Johnson & Johnson
JNJ
|
+$225M |
| 3 |
MON
Monsanto Co
MON
|
+$213M |
| 4 |
AET
Aetna Inc
AET
|
+$208M |
| 5 |
Broadcom
AVGO
|
+$176M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$227M |
| 2 |
Microsoft
MSFT
|
+$224M |
| 3 |
Alphabet (Google) Class C
GOOG
|
+$205M |
| 4 |
Nike
NKE
|
+$187M |
| 5 |
Pfizer
PFE
|
+$184M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 14.12% |
| 2 | Technology | 12.96% |
| 3 | Healthcare | 12.08% |
| 4 | Industrials | 11.23% |
| 5 | Consumer Staples | 8.62% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
TRCB
2976
DELISTED
Two River Bancorp
TRCB
| $221K | ﹤0.01% |
+15,540
| New | +$192K |
|
2977
Paramount Gold Nevada
PZG
$127M
| $220K | ﹤0.01% |
123,600
-55,300
| -31% | -$96.3K |
|
2978
Daily Journal
DJCO
$828M
| $218K | ﹤0.01% |
+900
| New | +$208K |
|
2979
Kornit Digital
KRNT
$827M
| $218K | ﹤0.01% |
+17,200
| New | +$198K |
|
2980
Fossil Group
FOSL
$330M
| $217K | ﹤0.01% |
+8,400
| New | +$253K |
|
|
SOFO
2981
DELISTED
Sonic Foundry, Inc. Common Stock
SOFO
| $217K | ﹤0.01% |
43,819
+900
| +2% | +$4.6K |
|
|
BBRG
2982
DELISTED
Bravo Brio Restaurant Group Inc.
BBRG
| $216K | ﹤0.01% |
+56,849
| New | +$241K |
|
|
UFAB
2983
DELISTED
Unique Fabricating, Inc.
UFAB
| $215K | ﹤0.01% |
14,700
-1,200
| -8% | -$16.4K |
|
2984
Eterna Therapeutics
ERNA
$5.02M
| $214K | ﹤0.01% |
2
+1
| +100% | +$120K |
|
2985
Protalix BioTherapeutics
PLX
$190M
| $213K | ﹤0.01% |
47,930
+29,840
| +165% | +$133K |
|
2986
Imperial Oil
IMO
$64B
| $212K | ﹤0.01% |
6,095
-249,995
| -98% | -$8.39M |
|
|
SMIT
2987
DELISTED
Schmitt Industries Inc
SMIT
| $212K | ﹤0.01% |
130,200
+8,500
| +7% | +$14.2K |
|
|
LMST
2988
DELISTED
Limestone Bancorp, Inc. Common Stock
LMST
| $211K | ﹤0.01% |
+17,162
| New | +$174K |
|
2989
NatWest
NWG
$76.9B
| $210K | ﹤0.01% |
35,286
-525,014
| -94% | -$2.82M |
|
2990
Imunon
IMNN
$6.64M
| $208K | ﹤0.01% |
250
+200
| +400% | +$456K |
|
|
AIFC
2991
AI Financial Corp
AIFC
$58.9M
| $208K | ﹤0.01% |
37,180
+2,140
| +6% | +$10.8K |
|
|
XPLR
2992
DELISTED
Xplore Technologies Corp.
XPLR
| $208K | ﹤0.01% |
103,000
+2,200
| +2% | +$4.9K |
|
2993
Curtiss-Wright
CW
$25.4B
| $207K | ﹤0.01% |
+2,100
| New | +$200K |
|
|
CMLS
2994
DELISTED
Cumulus Media Inc. Class A Common Stock
CMLS
| $207K | ﹤0.01% |
202,705
+117,110
| +137% | +$171K |
|
2995
First United
FUNC
$298M
| $206K | ﹤0.01% |
+12,900
| New | +$166K |
|
2996
Lisata Therapeutics
LSTA
$10.2M
| $206K | ﹤0.01% |
4,843
+2,900
| +149% | +$167K |
|
2997
eGain
EGAN
$206M
| $205K | ﹤0.01% |
97,400
+26,400
| +37% | +$67.2K |
|
|
EGT
2998
DELISTED
Entertainment Gaming Asia Inc.
EGT
| $205K | ﹤0.01% |
147,691
+11,900
| +9% | +$17.3K |
|
|
ECT
2999
DELISTED
ECA Marcellus Trust 1 Interest
ECT
| $204K | ﹤0.01% |
95,014
+76,836
| +423% | +$170K |
|
|
CBAY
3000
DELISTED
Cymabay Therapeutics
CBAY
| $203K | ﹤0.01% |
117,400
-3,400
| -3% | -$6K |
|
Similar funds
Jim Simons's Q4 2016 Portfolio in Review
As of Q4 2016, Jim Simons held 3,715 positions worth $63.2B, up 12% from $56.6B the previous quarter. Its ten largest holdings account for 7.2% of the portfolio.
Jim Simons deployed $5.07B of net new capital in Q4 2016, opening 418 new positions and adding to 1,792 existing holdings. Its largest new stake was Broadcom: 10,144,960 shares worth $179M.
By sector, the portfolio is most concentrated in Financials at 14% of assets, up from 12% a quarter earlier, followed by Technology and Healthcare.
On the sell side, the largest reduction was Bristol-Myers Squibb, an estimated $227M trimmed.
- Jim Simons's largest Q4 2016 buy was Broadcom: 10,144,960 shares worth $179M.
- Jim Simons added most to Gilead Sciences in Q4 2016, an estimated $247M increase.
- Jim Simons's biggest Q4 2016 reduction was Bristol-Myers Squibb, cutting an estimated $227M.
- Jim Simons fully exited Alphabet (Google) Class C in Q4 2016, selling an estimated $205M.
- Jim Simons's ten largest holdings make up 7.2% of its $63.2B portfolio in Q4 2016.
- Jim Simons opened 418 new positions and closed 494 in Q4 2016.
- Jim Simons's portfolio value rose 12% quarter-over-quarter to $63.2B.
Based on Renaissance Technologies's 13F filing for Q4 2016, filed 13 Feb 2017.